AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIV
AAV 载体递送具有针对 HIV 的最佳先天功能的广泛中和抗体
基本信息
- 批准号:10762553
- 负责人:
- 金额:$ 79.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-15 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAddressAnimal ExperimentsAnimal ModelAntibodiesAntibody-mediated protectionAutomobile DrivingBLT miceBindingBiological AssayBone MarrowCell physiologyCell surfaceCellsClinical TrialsDataDependovirusDoctor of PhilosophyEffectivenessEffector CellEngineeringEpitopesExhibitsFutureGene TransferGrantHIVHIV InfectionsHIV therapyHumanImmuneImmune systemImmunityImmunoglobulin FragmentsImmunoglobulin GIn VitroIndividualInfectionLiverMacrophageMeasuresMediatingMembrane FusionModelingMutationNatural ImmunityNatural Killer CellsNeutralization TestsNeutralizing antibody assayPatientsPatternPhagocytosisPopulationPreventionPrincipal InvestigatorResearchRoleSerumSideSpecificitySurfaceTechnologyTestingThymus GlandVaginaViralViremiaWorkadeno-associated viral vectorantibody engineeringantibody-dependent cell cytotoxicityantibody-dependent cellular phagocytosiscomparative efficacydelivery vehiclehumanized mouseimmunoengineeringimmunoprophylaxisin vitro Assayin vivoinnate immune functioninnate immune mechanismsmedical schoolsneutralizing antibodynext generationnovelpreventprofessorprotective efficacyreceptorreceptor bindingtransmission processvaginal transmissionvector
项目摘要
Project Summary / Abstract
This proposal describes the framework of an R01 grant for Alejandro Balazs, PhD. Dr. Balazs is
currently an assistant professor at Harvard Medical School working as a principal investigator at the Ragon
Institute of MGH, MIT & Harvard. Dr. Balazs’ research is focused on engineering the immune system via gene
transfer as a novel means of creating protection against HIV. Broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) show great promise in HIV prevention and therapy as they potently
neutralize a significant breadth of globally circulating HIV strains. A number of animal experiments and clinical
trials have demonstrated the ability of bNAbs to confer protection from viral challenge and reduce viremia of
established infections. BNAbs can inhibit HIV infection by blocking viral attachment or membrane fusion;
however, recent work suggests that the fragment crystallizable (Fc) region of antibodies may also contribute
significantly to bNAb-mediated HIV inhibition through interactions with innate immunity. This proposal seeks to
use in vitro cell-based assays to determine the extent to which next-generation HIV bNAbs engage effector
functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular
phagocytosis (ADCP). This proposal will modify the Vectored ImmunoProphylaxis technology pioneered by Dr.
Balazs to generate sustained expression of antibodies harboring precise Fc-region mutations previously
demonstrated to enhance or abrogate, Fc-receptor interactions. By manipulating the specificity and
concentration of these antibodies, this study will define the rules governing Fc-receptor engagement that apply
to prevention of HIV acquisition. Furthermore, it seeks to determine the potential for Fc-enhanced antibodies to
increase the potency of bNAb protection against HIV transmission. Finally, this proposal will manipulate the
immune system of humanized mice as a means of dissecting and precisely quantifying the contribution of
specific immune cells to prevention of HIV transmission. Together, this work will reveal optimal epitope targets
and innate immune mechanisms to produce next-generation AAV vectors encoding bNAbs with enhanced
innate immune function to prevent HIV transmission.
项目总结/摘要
该提案描述了Alejandro Balazs博士的R 01赠款框架。巴拉兹博士是
目前是哈佛医学院的助理教授,担任Ragon的首席研究员
麻省理工学院和哈佛麻省总医院研究所。巴拉兹博士的研究重点是通过基因工程免疫系统
转移作为一种新的保护艾滋病毒的手段。广泛中和抗体(bNAb)
人类免疫缺陷病毒(HIV)在HIV预防和治疗中显示出巨大前景,因为它们有效地
中和全球广泛传播的艾滋病毒毒株。多项动物实验和临床
试验已经证明了bNAb能够提供保护免受病毒攻击并减少病毒血症。
建立感染。BNAb可以通过阻断病毒附着或膜融合来抑制HIV感染;
然而,最近的研究表明,抗体的可结晶片段(Fc)区也可能有助于
通过与先天免疫的相互作用,bNAb介导的HIV抑制作用显著。这项建议旨在
使用基于细胞的体外试验来确定下一代HIV bNAb与效应子
功能,如抗体依赖性细胞毒性(ADCC)和抗体依赖性细胞毒性(CD 34)。
吞噬作用(ADCP)。该提案将修改由Dr.
Balazs产生先前携带精确Fc区突变的抗体的持续表达
证实增强或消除Fc-受体相互作用。通过操纵特异性,
这些抗体的浓度,本研究将定义适用于Fc受体结合的规则
预防艾滋病毒感染。此外,它试图确定Fc增强抗体的潜力,
提高bNAb预防艾滋病毒传播的效力。最后,这项建议将操纵
人源化小鼠的免疫系统作为解剖和精确定量
特异性免疫细胞预防艾滋病毒传播。总之,这项工作将揭示最佳表位靶点
和先天免疫机制,以产生编码具有增强的bNAb的下一代AAV载体。
先天免疫功能,以防止艾滋病毒的传播。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
mRNA-based monkeypox virus vaccine prevents disease in non-human primates.
基于 mRNA 的猴痘病毒疫苗可预防非人类灵长类动物的疾病。
- DOI:10.1016/j.cell.2024.02.011
- 发表时间:2024
- 期刊:
- 影响因子:64.5
- 作者:Nitido,AdamN;Balazs,AlejandroB
- 通讯作者:Balazs,AlejandroB
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alejandro Benjamin Balazs其他文献
Alejandro Benjamin Balazs的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alejandro Benjamin Balazs', 18)}}的其他基金
Development of Vectored ImmunoProphylaxis as a strategy against HIV
开发载体免疫预防作为抗 HIV 策略
- 批准号:
8411105 - 财政年份:2014
- 资助金额:
$ 79.69万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 79.69万 - 项目类别:
Research Grant